ES2170918T3 - Inhibidor de proteina quinasa c sustituidos con halo. - Google Patents

Inhibidor de proteina quinasa c sustituidos con halo.

Info

Publication number
ES2170918T3
ES2170918T3 ES97302996T ES97302996T ES2170918T3 ES 2170918 T3 ES2170918 T3 ES 2170918T3 ES 97302996 T ES97302996 T ES 97302996T ES 97302996 T ES97302996 T ES 97302996T ES 2170918 T3 ES2170918 T3 ES 2170918T3
Authority
ES
Spain
Prior art keywords
halo
protein
quinase
inhibitor
replaced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97302996T
Other languages
English (en)
Inventor
Peter G Goekjian
Michael R Jirousek
Guo-Zhang Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mississippi State University
Eli Lilly and Co
University of Mississippi
Original Assignee
Mississippi State University
Eli Lilly and Co
University of Mississippi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mississippi State University, Eli Lilly and Co, University of Mississippi filed Critical Mississippi State University
Application granted granted Critical
Publication of ES2170918T3 publication Critical patent/ES2170918T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A NUEVOS COMPUESTOS DE BIS INDOLMALEIMIDA HALO ON TAMBIEN SE REFIERE A UN METODO PARA LA PREPARACION DE LOS COMPUESTOS PRESENTADOS Y PARA LA PREPARACION DE UNA FORMULACION FARMACEUTICA A UTILIZAR EN LA INHIBICION DE LA CINASA C DE PROTEINAS EN MAMIFEROS.
ES97302996T 1996-05-01 1997-05-01 Inhibidor de proteina quinasa c sustituidos con halo. Expired - Lifetime ES2170918T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1638296P 1996-05-01 1996-05-01

Publications (1)

Publication Number Publication Date
ES2170918T3 true ES2170918T3 (es) 2002-08-16

Family

ID=21776838

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97302996T Expired - Lifetime ES2170918T3 (es) 1996-05-01 1997-05-01 Inhibidor de proteina quinasa c sustituidos con halo.

Country Status (21)

Country Link
US (1) US5936084A (es)
EP (1) EP0805158B1 (es)
JP (1) JP3235840B2 (es)
KR (1) KR20000065137A (es)
AT (1) ATE212026T1 (es)
AU (1) AU703395B2 (es)
BR (1) BR9709301A (es)
CA (1) CA2252701C (es)
CZ (1) CZ347098A3 (es)
DE (1) DE69709568T2 (es)
DK (1) DK0805158T3 (es)
EA (1) EA001450B1 (es)
ES (1) ES2170918T3 (es)
IL (1) IL126762A0 (es)
NO (1) NO310416B1 (es)
NZ (1) NZ332658A (es)
PL (1) PL329681A1 (es)
PT (1) PT805158E (es)
TR (1) TR199802193T2 (es)
WO (1) WO1997041127A1 (es)
YU (1) YU48398A (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127401A (en) 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles
US7425537B2 (en) * 2000-08-22 2008-09-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services SH2 domain binding inhibitors
DE60112611T2 (de) * 2000-12-08 2006-06-14 Ortho Mcneil Pharm Inc Makroheterocyclische verbindungen als kinase inhibitoren
JP2005508365A (ja) * 2001-10-29 2005-03-31 ネクター セラピューティックス エイエル，コーポレイション プロテインキナーゼｃインヒビターのポリマー結合体
PL375552A1 (en) * 2002-05-22 2005-11-28 Amgen Inc. Vanilloid receptor ligands and their medical applications
EP2270006A1 (en) * 2002-08-08 2011-01-05 Amgen, Inc Pyridazine derivatives useful as vanilloid receptor ligands
DE10244453A1 (de) * 2002-09-24 2004-04-01 Phenomiques Gmbh Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten
US7245117B1 (en) * 2004-11-01 2007-07-17 Cardiomems, Inc. Communicating with implanted wireless sensor
JP2007522233A (ja) 2004-02-11 2007-08-09 アムジエン・インコーポレーテツド バニロイド受容体リガンド及び治療におけるそれらの使用
MY139645A (en) 2004-02-11 2009-10-30 Amgen Inc Vanilloid receptor ligands and their use in treatments
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
MX2007003085A (es) 2004-09-14 2007-08-02 Pharmasset Inc Preparacion de 2'-fluoro-2'-alquilo sustituido u otras ribofuranosil pirimidinas y purinas opcionalmente sustituidas y sus derivados.
WO2006089311A1 (en) * 2005-02-15 2006-08-24 Amgen Inc. Vanilloid receptor ligands and their use in treatments
WO2006108270A1 (en) * 2005-04-11 2006-10-19 Pharmagap Inc. Inhibitors of protein kinases and uses thereof
WO2006113769A1 (en) * 2005-04-15 2006-10-26 Amgen Inc. Vanilloid receptor ligands and their use in treatments
WO2010049947A2 (en) * 2008-10-28 2010-05-06 Accrete Pharmaceutical Private Limited Preparation of gemcitabine and intermediates thereof
ES2668775T3 (es) * 2009-06-10 2018-05-22 Chugai Seiyaku Kabushiki Kaisha Compuestos tetracíclicos
MX355836B (es) 2010-08-20 2018-05-02 Chugai Pharmaceutical Co Ltd Composicion que comprende compuestos tetraciclicos.
US10668075B2 (en) 2012-09-25 2020-06-02 Chugai Seiyaku Kabushiki Kaisha RET inhibitor
EP3135671B1 (en) 2014-04-25 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Novel crystal of tetracyclic compound
WO2015163448A1 (ja) 2014-04-25 2015-10-29 中外製薬株式会社 ４環性化合物を高用量含有する製剤
TWI831347B (zh) 2014-08-08 2024-02-01 日商中外製藥股份有限公司 包含４環性化合物的非晶質體之固體分散體及製劑
JP6741596B2 (ja) 2015-01-16 2020-08-19 中外製薬株式会社 併用医薬
WO2019000224A1 (zh) * 2017-06-27 2019-01-03 中国海洋大学 双吲哚马来酰亚胺衍生物及其制备方法和用途
CN112384223B (zh) 2018-06-29 2024-08-27 中外制药株式会社 含有难溶性碱性药剂的药物组合物
WO2020050241A1 (ja) 2018-09-04 2020-03-12 中外製薬株式会社 ４環性化合物の製造方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5438050A (en) * 1988-02-06 1995-08-01 Godecke Aktiengesellschaft Indolocarbazole derivatives, processes for their preparation and compositions containing them
US5380746A (en) * 1989-05-05 1995-01-10 Goedecke Aktiengesellschaft Bis-(1H-indol-3-YL)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
US5589472A (en) * 1992-09-25 1996-12-31 Vice; Susan F. Diindolo compounds and pharmaceutical compositions containing them
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
PL182124B1 (pl) * 1993-12-07 2001-11-30 Lilly Co Eli Nowe zwiazki oraz srodek farmaceutyczny przeznaczony do leczenia powiklan cukrzycowych lub do leczenia nowotworów PL PL PL PL PL PL PL PL
US5472183A (en) * 1994-03-17 1995-12-05 Nisca Corporation Sheet feeding device with multiple sheet stackers
US5559228A (en) * 1995-03-30 1996-09-24 Eli Lilly And Company Synthesis of bisindolylmaleimides
US5696949A (en) * 1995-06-15 1997-12-09 Intel Corporation System for PCI slots expansion using asynchronous PCI-to-PCI bridge with clock generator for providing clock signal to the expansion mother board and expansion side of bridge

Also Published As

Publication number Publication date
AU2929297A (en) 1997-11-19
EP0805158A2 (en) 1997-11-05
CA2252701C (en) 2003-10-28
NO985080L (no) 1998-12-08
YU48398A (sh) 2000-12-28
ATE212026T1 (de) 2002-02-15
JPH11509233A (ja) 1999-08-17
BR9709301A (pt) 1999-08-10
PL329681A1 (en) 1999-04-12
NO985080D0 (no) 1998-10-30
TR199802193T2 (xx) 1999-02-22
EP0805158A3 (en) 1998-04-01
PT805158E (pt) 2002-06-28
IL126762A0 (en) 1999-08-17
KR20000065137A (ko) 2000-11-06
DK0805158T3 (da) 2002-03-18
EA199800966A1 (ru) 1999-04-29
WO1997041127A1 (en) 1997-11-06
NO310416B1 (no) 2001-07-02
AU703395B2 (en) 1999-03-25
EA001450B1 (ru) 2001-04-23
EP0805158B1 (en) 2002-01-16
JP3235840B2 (ja) 2001-12-04
CZ347098A3 (cs) 1999-06-16
CA2252701A1 (en) 1997-11-06
US5936084A (en) 1999-08-10
NZ332658A (en) 2000-05-26
DE69709568T2 (de) 2002-09-05
DE69709568D1 (de) 2002-02-21

Similar Documents

Publication Publication Date Title
ES2162843T3 (es) Inhibidores de la proteina quinasa c.
PT758248E (pt) Formulacoes para o factor ix
ES2122764T3 (es) Inhibidor de la proteina quinasa c.
GT199900102A (es) Fenoxipropanolaminas, procedimiento para su preparacìon y composiciones farmacèuticasque las contienen.
ES2144151T3 (es) Benzotiazepinas hipolipidemicas.
MX9700082A (es) Composicion que consiste de morfina, polipirrolidona y oxido de polialquileno.
PA8353701A1 (es) Procedimiento y forma cristalinas de 2-metil-tieno-benzodiacepina.
UY25242A1 (es) Inhibidores de benzotiazol de la proteína tirosina cinasa
HN1997000072A (es) Procedimiento para la preparacion de sildenafil
NO990548L (no) Inhibitorer for cystein-protease
ES2144192T3 (es) Nuevos derivados de 1-fenil-2-dimetil-amino-metil-ciclohexan-1-ol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
MX9701342A (es) Formulacion cosolvente de tirilazad para administracion parenteral.
ES2177642T3 (es) Uso de ciertos derivados de acido metanobisfosfonico para prevenir el desprendimiento y la migracion de protesis.
ES2194107T3 (es) Formulaciones farmaceuticas y dieteticas para la profilaxis y tratamiento de trastornos gastrointestinales.
CU22776A3 (es) D-manitol y su preparación
ES2160680T3 (es) Utilizacion de un antagonista de sustancia p en una composicion farmaceutica.
SE9601556D0 (sv) New pharmaceutical formulation of a thrombin inhibitor for parenteral use
AR003451A1 (es) Derivados de piperazina, una composicion farmaceutica que los comprende, el uso de los mismos y un metodo para su preparacion.
PA8469101A1 (es) Ligandos azabiciclicos de receptores 5ht1
ES2147427T3 (es) Aminas ciclicas n-sustituidas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen.
ECSP941120A (es) Derivados de 1,5 benzodiazepina
ES2170143T3 (es) Composiciones que comprenden halofantrina en una forma especial.
ES2132556T3 (es) Nuevo derivado de benzo-tiadiazina, su procedimiento de preparacion y las composiciones farmaceuticas que lo contienen.
CO4600682A1 (es) Protrombinas como antidoto para los inhibidores de la trom- bina
MX9704034A (es) Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 805158

Country of ref document: ES